Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work ...

CME Group, the world's leading derivatives marketplace, announced its new Avalanche (AVAX) and Sui (SUI) futures are now available for trading. First trades were executed as blocks between FalconX and ...

While the portal, as adopted, reflects some of the changes AASA asked for, it still represents a redundant element of the ...

How the nonprofit's comprehensive K-12 curriculum has already helped 30,000 students – and hopes to reach all of South Dakota ...

The Medicare GLP-1 Bridge program will cover weight loss drugs for a $50 monthly copay for eligible beneficiaries through Dec. 31, 2027. Medicare currently does not cover GLP-1 drugs for weight loss ...

Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

Q1 2026 earnings call highlights: revenue, EBITDA, guidance, NARCAN and international MCM growth, plus debt moves—read now.

First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% ...

It’s clear that AI is having a more profound impact on an increasing number of industries. In healthcare, finance and ...

Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (NASDAQ: SABS) to support the process development and manufacturing of SAB-142, SAB BIO’s ...

Under the terms of the agreement, Emergent will provide end-to-end development and manufacturing services to SAB BIO that are compliant with current good manufacturing practices. These services will ...